| Sex, male, n (%) |
22(44.00%) |
36(51.43%) |
ns |
| Age (y), mean ± SD |
4.35±3.20 (2-5 years) |
9.07±1.67 (6-12 years) |
<0.0001 |
| Weight (kg), range |
18.01(12.00-25.00) |
35.00(20.00-67.00) |
<0.0001 |
| BMI (kg/m2), mean ± SD |
16.22(±2.45) |
17.98(±3.27) |
0.0102 |
| Duration of AD (y), mean ± SD |
3.20(±1.52) |
5.83(±2.95) |
<0.0001 |
| Extrinsic status, n (%) |
43(86.00%) |
66(94.29%) |
ns |
| Phenotypes, n (%) |
|
|
|
| Erythemato-desquamative |
18(36.00%) |
23(32.86%) |
ns |
| Head and neck dermatitis |
15(30.00%) |
20(28,57%) |
ns |
| Lichenification |
7(14.00%) |
13(18.57%) |
ns |
| Exudative eczema |
7(14.00%) |
10(14.29%) |
ns |
| Prurigo nodularis-like |
3(6.00%) |
4(5.71%) |
ns |
| Family History of Allergy, n (%) |
17(34.00%) |
20(28.57%) |
ns |
| Atopic/allergic diseases concomitant, n (%) |
28(56.00%) |
42(60.00%) |
ns |
| Allergic rhinitis |
14(28.00%) |
20(28.57%) |
|
| Asthma |
5(10.00%) |
7(10.00%) |
|
| Allergic conjunctivitis |
0 |
3(4.29%) |
|
| Urticaria |
2(4.00%) |
1(1.43%) |
|
| History of systemic medication for AD, n (%) |
50(100.00%) |
70(100.00%) |
ns |
| Systemic corticosteroids |
0 |
4(5.71%) |
|
| Antihistamines |
50(100.00%) |
70(100%) |
|
| Non-steroidal immunosuppressants |
0 |
0 |
|
| Traditional Chinese medicine |
10(20.00%) |
19(27.14%) |
ns |
| History of topical medication for AD, n (%) |
50(100%) |
70(100%) |
ns |
| Topical corticosteroids |
50(100%) |
70(100%) |
|
| Topical calcineurin inhibitors |
35(70.00%) |
50(71.43%) |
|
| Phosphodiesterase 4 (PDE4) inhibitors |
9(18.00%) |
9(12.86%) |
|
| Concomitant topical medications, n (%) |
27(54.00%) |
39(55.71%) |
ns |
| Topical corticosteroids |
16(32.00%) |
2840.00%) |
|
| Topical calcineurin inhibitors |
12(24.00%) |
20(28.57%) |
|
| Phosphodiesterase 4 (PDE4) inhibitors |
4(8.00%) |
4(5.71%) |
|
| Comorbidities, n (%) |
2(4.00%) |
3(4.29%) |
ns |
| Chronic hepatitis B |
0 |
1(1.43%) |
|
| Alopecia areata |
0 |
1(1.43%) |
|
| Epilepsy |
0 |
1(1.43%) |
|
| Eosinophilic esophagitis |
1(2.00%) |
0 |
|
| Vitiligo |
1(2.00%) |
0 |
|
| Total IgE level (IU/ml) at baseline, mean ± SD |
1663.32(±2353.16) |
1698.90(±2711.52) |
ns |
|
Number of circulating eosinophils (×10^9/L), mean ±
SD
|
0.67(±0.49) |
0.69(±0.56) |
ns |
| Clinical scores at baseline, mean ± SD |
|
|
|
| IGA |
3.80(±0.40) |
3.67(±0.47) |
ns |
| SCORAD |
51.33(±13.95) |
53.18(±18.21) |
ns |
| EASI |
18.81(±12.39) |
19.27(±14.84) |
ns |
| CDLQI (IDQoL)* |
10.20(±4.62) |
10.86(±6.90) |
ns |